Cylex Experiences Dramatic Revenue Growth in First Half of 2008

In the first six months of 2008, Cylex revenue rose from $2.16 million to $3.65 million, representing a gain of 69%.

The gain reflected increasing awareness of the usefulness of the company's innovative diagnostic tests among current customers, initial purchases by several highly prestigious medical centers and a larger sales force that is generating enhanced attention among customers and prospects.

About Cylex Incorporated®
Cylex is a global life science company that develops and manufactures research and in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow® is an in vitro diagnostic utilized to detect cell mediated immunity in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the country. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers and companion assays.